HCW Biologics Inc
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat p… Read more
HCW Biologics Inc (HCWB) - Total Assets
Latest total assets as of September 2025: $25.45 Million USD
Based on the latest financial reports, HCW Biologics Inc (HCWB) holds total assets worth $25.45 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
HCW Biologics Inc - Total Assets Trend (2019–2024)
This chart illustrates how HCW Biologics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
HCW Biologics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
HCW Biologics Inc's total assets of $25.45 Million consist of 18.9% current assets and 81.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 15.5% |
| Accounts Receivable | $582.20K | 1.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how HCW Biologics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HCW Biologics Inc's current assets represent 18.9% of total assets in 2024, a decrease from 79.8% in 2019.
- Cash Position: Cash and equivalents constituted 15.5% of total assets in 2024, down from 73.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 1.9% of total assets.
HCW Biologics Inc Competitors by Total Assets
Key competitors of HCW Biologics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
HCW Biologics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - HCW Biologics Inc generates 0.08x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - HCW Biologics Inc is currently not profitable relative to its asset base.
HCW Biologics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.06 | 0.07 | 12.14 |
| Quick Ratio | 0.06 | 0.07 | 11.60 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-25.27 Million | $ -27.97 Million | $ 11.15 Million |
HCW Biologics Inc - Advanced Valuation Insights
This section examines the relationship between HCW Biologics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.80 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 6.0% |
| Total Assets | $30.24 Million |
| Market Capitalization | $1.20 Million USD |
Valuation Analysis
Below Book Valuation: The market values HCW Biologics Inc's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: HCW Biologics Inc's assets grew by 6.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for HCW Biologics Inc (2019–2024)
The table below shows the annual total assets of HCW Biologics Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $30.24 Million | +6.04% |
| 2023-12-31 | $28.51 Million | -39.09% |
| 2022-12-31 | $46.81 Million | -12.53% |
| 2021-12-31 | $53.51 Million | +247.54% |
| 2020-12-31 | $15.40 Million | +52.97% |
| 2019-12-31 | $10.07 Million | -- |